Nearly half a million people in the United States suffer from an intestinal infection called Clostridium difficile each year. Approximately half of those individuals become sick enough to require ...

Minnie Hatch, 29, from Salt Lake City, had painful stomach cramps, and other symptoms for months before finding out she had Clostridioides difficile, or C. diff. These bacteria can grow out of control ...

A study published in the Journal of Hospital Medicine shows clinical history, especially a history of immunodeficiency, is a better diagnosis tool for Clostridium difficile in pediatric patients than ...

Researchers from the University of Virginia in Charlottesville have discovered a type of gut bacteria that could prove effective where other types of helpful bacteria have failed in the fight against ...

Some people will get repeat infections from Clostridium difficile (C. diff). They may develop the same symptoms they had before such as diarrhea, stomach pain, and loss of appetite. However, the only ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

A new microbiome-based treatment for Clostridioides difficile infection showed success in reducing recurrence of the infection at 8 weeks, according to preliminary results released by the manufacturer ...

With each recurrence, risk of another rises, with more weight loss, diarrhea and fatigue. After a third recurrence, the risk of suffering a fourth is 60 percent to 70 percent. "It's a constant wheel ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...